Twitter | Search | |
Gibson Oncology, LLC
Tough on not on Patients. Initiating Phase II trials on the Indenoisoquinolines, a new class of non-Camptothecins a novel anti-cancer fighting drug.
3
Tweets
5
Following
1
Followers
Tweets
Gibson Oncology, LLC Dec 12
Gibson’s Novel Anti-cancer Drug, LMP-400, Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing Sarcoma For more info about please visit our website:
Reply Retweet Like
Gibson Oncology, LLC Dec 11
Gibson Oncology Adds Two Prominent Experts on Indenoisoquinolines to its Board of Directors. Read in full:
Reply Retweet Like
Gibson Oncology, LLC Dec 11
Acquires Novel Anti-Cancer Drugs from Linus Oncology. MIAMI-(BUSINESS WIRE)-(“Gibson”) a privately held clinical stage company, acquired three (3) clinical I drugs from Linus Oncology.
Reply Retweet Like